XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
出版年份 2021 全文链接
标题
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
作者
关键词
-
出版物
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-08-12
DOI
10.1186/s13046-021-02044-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance
- (2019) Eylem Kulkoyluoglu-Cotul et al. Cancers
- Current management of neuroblastoma and future direction
- (2019) Elizabeth R. Pastor et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models
- (2018) Cristina Corno et al. BIOCHEMICAL PHARMACOLOGY
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
- (2018) Ujjawal H. Gandhi et al. Clinical Lymphoma Myeloma & Leukemia
- Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
- (2018) Abbey R. Sadowski et al. BMC Veterinary Research
- Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death
- (2018) Joshua M. Marcus et al. CELL CYCLE
- Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis
- (2018) Dongqing Yan et al. CLINICAL CANCER RESEARCH
- The challenge of defining “ultra-high-risk” neuroblastoma
- (2018) Daniel A. Morgenstern et al. PEDIATRIC BLOOD & CANCER
- Overview and recent advances in the treatment of neuroblastoma
- (2017) Sarah B. Whittle et al. Expert Review of Anticancer Therapy
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
- (2016) Xuejiao Liu et al. Journal of Hematology & Oncology
- Neuroblastoma
- (2016) Katherine K. Matthay et al. Nature Reviews Disease Primers
- Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
- (2015) Winnie Yeo et al. BMC CANCER
- Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
- (2015) S. Kazim et al. MOLECULAR CANCER THERAPEUTICS
- HISAT: a fast spliced aligner with low memory requirements
- (2015) Daehwan Kim et al. NATURE METHODS
- Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program
- (2015) Edward F. Attiyeh et al. PEDIATRIC BLOOD & CANCER
- Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein
- (2015) Jo Ishizawa et al. PHARMACOLOGY & THERAPEUTICS
- Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
- (2014) Megan N Breit et al. BMC Veterinary Research
- KPT-330 has antitumour activity against non-small cell lung cancer
- (2014) H Sun et al. BRITISH JOURNAL OF CANCER
- Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
- (2014) L Chen et al. BRITISH JOURNAL OF CANCER
- Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
- (2014) Mariko Yoshimura et al. CANCER SCIENCE
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
- (2014) Kaushal Parikh et al. Journal of Hematology & Oncology
- XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
- (2014) Y. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
- (2014) Cheryl A. London et al. PLoS One
- Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
- (2014) Jennifer Yang et al. PLoS One
- Clinical translation of nuclear export inhibitors in cancer
- (2014) William T. Senapedis et al. SEMINARS IN CANCER BIOLOGY
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1
- (2013) Qingxiang Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth
- (2012) Hiromi Inoue et al. JOURNAL OF UROLOGY
- NESdb: a database of NES-containing CRM1 cargoes
- (2012) Darui Xu et al. MOLECULAR BIOLOGY OF THE CELL
- Fast gapped-read alignment with Bowtie 2
- (2012) Ben Langmead et al. NATURE METHODS
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- (2011) Bo Li et al. BMC BIOINFORMATICS
- Structural basis for leucine-rich nuclear export signal recognition by CRM1
- (2009) Xiuhua Dong et al. NATURE
- SOAP: short oligonucleotide alignment program
- (2008) R. Li et al. BIOINFORMATICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now